UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Summary

This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams

Timeline

Start

2017-04-03

Primary completion

2022-05-30

Completion

2022-05-30

Outcome

Outcome not reported

Stopped (Enrollment): “lack of accrual reevaluating feasibility”

Drugs

Indications